Sadri Maryam, Shafaghat Zahra, Roozbehani Mona, Hoseinzadeh Akram, Mohammadi Fatemeh, Arab Fahimeh Lavi, Minaeian Sara, Fard Soheil Rahmani, Faraji Fatemeh
Department of Immunology, Iran University of Medical Sciences, Tehran, Iran.
Vaccine Research Center, Iran University of Medical Sciences, Tehran, Iran.
Probiotics Antimicrob Proteins. 2025 Jun;17(3):1688-1710. doi: 10.1007/s12602-024-10431-z. Epub 2024 Dec 30.
Various types of liver or hepatic diseases cause the death of about 2 million people worldwide every year, of which 1 million die from the complications of cirrhosis and another million from hepatocellular carcinoma and viral hepatitis. Currently, the second most common solid organ transplant is the liver, and the current rate represents less than 10% of global transplant requests. Hence, finding new approaches to treat and prevent liver diseases is essential. In liver diseases, the interaction between the liver, gut, and immune system is crucial, and probiotics positively affect the human microbiota. Probiotics are a non-toxic and biosafe alternative to synthetic chemical compounds. Health promotion by lowering cholesterol levels, stimulating host immunity, the natural gut microbiota, and other functions are some of the activities of probiotics, and their metabolites, including bacteriocins, can exert antimicrobial effects against a broad range of pathogenic bacteria. The present review discusses the available data on the results of preclinical and clinical studies on the effects of probiotic administration on different types of liver diseases.
每年，全球约有200万人死于各种类型的肝脏疾病，其中100万人死于肝硬化并发症，另外100万人死于肝细胞癌和病毒性肝炎。目前，肝脏是第二常见的实体器官移植对象，而当前的移植率不到全球移植需求的10%。因此，寻找治疗和预防肝脏疾病的新方法至关重要。在肝脏疾病中，肝脏、肠道和免疫系统之间的相互作用至关重要，而益生菌对人类微生物群有积极影响。益生菌是合成化学化合物的无毒且生物安全的替代品。降低胆固醇水平、刺激宿主免疫力、调节天然肠道微生物群等促进健康的功能是益生菌的部分活性，其代谢产物，包括细菌素，可对多种病原菌发挥抗菌作用。本综述讨论了关于益生菌给药对不同类型肝脏疾病影响的临床前和临床研究结果的现有数据。
